153 related articles for article (PubMed ID: 26629319)
1. Caldecrin: A pancreas-derived hypocalcemic factor, regulates osteoclast formation and function.
Tomomura M; Tomomura A
World J Biol Chem; 2015 Nov; 6(4):358-65. PubMed ID: 26629319
[TBL] [Abstract][Full Text] [Related]
2. Purification and Biological Function of Caldecrin.
Tomomura A; Bandow K; Tomomura M
Medicines (Basel); 2021 Jul; 8(8):. PubMed ID: 34436220
[TBL] [Abstract][Full Text] [Related]
3. Serum calcium-decreasing factor, caldecrin, inhibits receptor activator of NF-κB ligand (RANKL)-mediated Ca2+ signaling and actin ring formation in mature osteoclasts via suppression of Src signaling pathway.
Tomomura M; Hasegawa H; Suda N; Sakagami H; Tomomura A
J Biol Chem; 2012 May; 287(22):17963-74. PubMed ID: 22461633
[TBL] [Abstract][Full Text] [Related]
4. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.
Hasegawa H; Kido S; Tomomura M; Fujimoto K; Ohi M; Kiyomura M; Kanegae H; Inaba A; Sakagami H; Tomomura A
J Biol Chem; 2010 Aug; 285(33):25448-57. PubMed ID: 20547767
[TBL] [Abstract][Full Text] [Related]
5. Caldecrin is a novel-type serine protease expressed in pancreas, but its homologue, elastase IV, is an artifact during cloning derived from caldecrin gene.
Yoshino-Yasuda I; Kobayashi K; Akiyama M; Itoh H; Tomomura A; Saheki T
J Biochem; 1998 Mar; 123(3):546-54. PubMed ID: 9538241
[TBL] [Abstract][Full Text] [Related]
6. Determination of amino acid sequence responsible for suppression of bone resorption by serum calcium-decreasing factor (caldecrin).
Tomomura A; Yamada H; Fujimoto K; Inaba A; Katoh S
FEBS Lett; 2001 Nov; 508(3):454-8. PubMed ID: 11728471
[TBL] [Abstract][Full Text] [Related]
7. Molecular cloning and expression of serum calcium-decreasing factor (caldecrin).
Tomomura A; Tomomura M; Fukushige T; Akiyama M; Kubota N; Kumaki K; Nishii Y; Noikura T; Saheki T
J Biol Chem; 1995 Dec; 270(51):30315-21. PubMed ID: 8530454
[TBL] [Abstract][Full Text] [Related]
8. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
9. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
10. Caldecrin inhibits lipopolysaccharide-induced pro-inflammatory cytokines and M1 macrophage polarization through the immunoreceptor triggering receptor expressed in myeloid cells-2.
Bandow K; Hasegawa H; Tomomura M; Tomomura A
Biochem Biophys Res Commun; 2020 Mar; 523(4):1027-1033. PubMed ID: 31973822
[TBL] [Abstract][Full Text] [Related]
11. Rat brain expresses serum calcium-decreasing factor (caldecrin).
Tomomura A; Yamada H; Itagaki K; Fujimoto K; Katoh S
Neurosci Lett; 2002 Jan; 317(1):17-20. PubMed ID: 11750986
[TBL] [Abstract][Full Text] [Related]
12. Molecular cloning and expression of human caldecrin.
Tomomura A; Akiyama M; Itoh H; Yoshino I; Tomomura M; Nishii Y; Noikura T; Saheki T
FEBS Lett; 1996 May; 386(1):26-8. PubMed ID: 8635596
[TBL] [Abstract][Full Text] [Related]
13. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
[TBL] [Abstract][Full Text] [Related]
14. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
15. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
16. Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.
Dou C; Chen Y; Ding N; Li N; Jiang H; Zhao C; Kang F; Cao Z; Quan H; Luo F; Xu J; Dong S
Osteoporos Int; 2016 Jul; 27(7):2335-2344. PubMed ID: 26809192
[TBL] [Abstract][Full Text] [Related]
17. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
Baek JM; Kim JY; Yoon KH; Oh J; Lee MS
Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631
[TBL] [Abstract][Full Text] [Related]
18. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
19. Water extract of
Shim KS; Kim T; Ha H; Lee CJ; Lee B; Kim HS; Park JH; Ma JY
Integr Med Res; 2015 Jun; 4(2):102-111. PubMed ID: 28664115
[TBL] [Abstract][Full Text] [Related]
20. Pyridone 6, a pan-Janus-activated kinase inhibitor, suppresses osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T cells (NFAT) c1 expression.
Kwak HB; Kim HS; Lee MS; Kim KJ; Choi EY; Choi MK; Kim JJ; Cho HJ; Kim JW; Bae JM; Kim YK; Park BH; Ha H; Chun CH; Oh J
Biol Pharm Bull; 2009 Jan; 32(1):45-50. PubMed ID: 19122279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
